The patient perspective has become even more important in the wake of the pandemic. Here’s how Clinica Dermacross is making it a priority.
Dr. Kelly Cordoro’s research on pediatric psoriasis shows it may be time to rethink our expectations about comorbidities and treatment.
In 2022, the IPC advanced in the worldwide psoriasis community, ranging from multiple research efforts, education of dermatologists, and public awareness, reaching the patient communities. In addition to face-to-face events, the IPC has expanded its digital presence. Read some of IPC’s significant achievements from the past year and leave a comment letting us know what topics you want to see on the IPC website in the coming year!
International Psoriasis Councils’ Psoriasis Severity Reclassification Project aims to change the classification of psoriasis severity. IPC’s network of key opinion leaders agreed on a definition for each category of disease severity.
European Commission grants conditional marketing authorization based on the EFFISAYIL® 1 trial, which showed over half of the spesolimab-treated patients were free of pustules, one week after receiving a single dose. This decision builds on existing approvals in the United States and Japan.
This revised statement is based on expert opinion and should be interpreted in the context of local policies and emerging evidence.
Recently, a study was conducted on the effect of apremilast on vascular inflammation and cardiometabolic functions with an impressively comprehensive set of markers for vascular inflammation and cardiometabolic disease. Peter van de Kerkhof, MD, PhD, provides his expert opinion on the overall conclusion and the implications of this study are discussed.
Recurrent flares, painful fiery-red skin, and sterile pustules — are the characteristics of Generalized Pustular Psoriasis (GPP), a rare and potentially life-threatening autoinflammatory disease.
Biologics and biosimilars have created many new options in psoriasis treatment for patients worldwide, but patients worldwide face barriers to acquiring them. This has led IPC Councilor Dr. Matias Maskin to reconsider what success means for psoriasis patients.
The International Psoriasis Council (IPC) and Scientific Education Support (SES) are excited to announce a strategic collaboration aimed to improve awareness, knowledge, and understanding of psoriasis, psoriatic arthritis, and other related diseases.
The monkeypox outbreak has had a significant impact all across the globe. Here’s what to know about monkeypox symptoms, treatment, and prevention.
The European Academy of Dermatology and Venereology (EADV) organized its 31st congress in Milano, Italy, under the parole “Designing the Future of Dermatology and Venereology.” The event took place from September 7 – 10, 2022, as a hybrid meeting with the option of attending virtually or in person. The following congress report includes fifteen summaries of presentations focusing on psoriasis. You can download the full report or read the summary.
